LetterLetter
Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
DESPOINA N. MARITSI, OLGA VOUGIOUKA and DESPINA ELEFTHERIOU
The Journal of Rheumatology April 2020, 47 (4) 634-635; DOI: https://doi.org/10.3899/jrheum.190011
DESPOINA N. MARITSI
Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia,
Cyprus;
MD, PhD, MRCPCHOLGA VOUGIOUKA
Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens,
Greece;
MD, PhDDESPINA ELEFTHERIOU
UCL–Great Ormond Street–Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London,
UK.
MD, PhD, MRCPCHREFERENCES
- 1.↵
- 2.↵
- Petty RE,
- Southwood TR,
- Manners P
- 3.↵
- 4.↵
- Brunner HI,
- Lovell DJ,
- Finck BK,
- Giannini EH
- 5.↵
- Vastert SJ,
- de Jager W,
- Noordman BJ,
- Holzinger D,
- Kuis W,
- Prakken BJ,
- et al.
- 6.↵
- Otten MH,
- Prince FH,
- Anink J,
- Ten Cate R,
- Hoppenreijs EP,
- Armbrust W,
- et al.
- 7.↵
- Woerner A,
- Uettwiller F,
- Melki I,
- Mouy R,
- Wouters C,
- Bader-Meunier B,
- et al.
- 8.↵
- 9.↵
- Ruperto N,
- Brunner HI,
- Quartier P,
- Constantin T,
- Wulffraat NM,
- Horneff G,
- et al.
- 10.↵
- Sota J,
- Insalaco A,
- Cimaz R,
- Alessio M,
- Cattalini M,
- Gallizzi R,
- et al.
In this issue
The Journal of Rheumatology
Vol. 47, Issue 4
1 Apr 2020
Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
DESPOINA N. MARITSI, OLGA VOUGIOUKA, DESPINA ELEFTHERIOU
The Journal of Rheumatology Apr 2020, 47 (4) 634-635; DOI: 10.3899/jrheum.190011